Cardiovascular and Thoracic Department, San Raffaele Scientific Institute and Università Vita-Salute, Milan, Italy.
Int J Cardiol. 2013 Sep 20;168(1):281-6. doi: 10.1016/j.ijcard.2012.09.079. Epub 2012 Nov 10.
TAVI is the alternative option in pts with AS deemed ineligible for surgery. Although mortality and morbidity are measures to assess the effectiveness of treatments, quality of life (QOL) should be an additional target. We assessed clinical outcome and QOL in octogenarians following TAVI.
All octogenarians with a risk profile considered by the Heart Team to be unacceptable for surgery entered in this registry. QOL was assessed by questionnaires concerning physical and psychic performance.
A hundred forty-five octogenarians (age: 84.7 ± 3.4 years; male: 48.3%) underwent TAVI for AS (97.2%) or isolated AR (2.8%). NYHA class: 2.8 ± 0.6; Logistic EuroScore: 26.1 ± 16.7; STS score: 9.2 ± 7.7.Echocardiographic assessments included AVA (0.77 ± 0.21 cm2), mean/peak gradients (54.5 ± 12.2/88 ± 19.5 mm Hg), LVEF (21%=EF ≤ 40%), sPAP (43.1 ± 11.6 mmHg).
All pts underwent successful TAVI using Edward-SAPIEN valve (71.2%) or Medtronic CoreValve (28.8%).
Rates of mortality at 30 days, 6 months and 1 year were 2.8%, 11.2% and 17.5%.
At 16-month follow up, 85.5% survived showing improved NYHA class (2.8 ± 0.6 vs 1.5 ± 0.7; p<0.001), decreased sPAP (43.1 ± 11.6 mm Hg vs 37.1 ± 7.7 mm Hg; p<0.001) and increased LVEF in those with EF ≤ 40% (34.9 ± 6% vs 43.5 ± 14.4%; p=0.006). Concerning QOL, 49% walked unassisted, 79% (39.5% among pts ≥ 85 years) reported self-awareness improvement; QOL was reported as "good" in 58% (31.4% among pts ≥ 85 years), "acceptable according to age" in 34% (16% among pts ≥ 85 years) and "bad" in 8%.
TAVI procedures improve clinical outcome and subjective health-related QOL in very elderly patients with symptomatic AS.
在被认为不适合手术的严重主动脉瓣狭窄(AS)患者中,TAVI 是一种替代选择。尽管死亡率和发病率是评估治疗效果的指标,但生活质量(QOL)也应该是一个额外的目标。我们评估了接受 TAVI 的 80 岁以上患者的临床结果和 QOL。
所有被心脏团队认为不适合手术的 80 岁以上高危患者均被纳入该登记处。QOL 通过涉及身体和精神表现的问卷进行评估。
145 名 80 岁以上(年龄:84.7 ± 3.4 岁;男性:48.3%)患者因 AS(97.2%)或孤立性主动脉瓣反流(2.8%)接受 TAVI。纽约心脏协会(NYHA)心功能分级:2.8 ± 0.6;欧洲心脏手术风险评分(EuroSCORE):26.1 ± 16.7;STS 评分:9.2 ± 7.7。超声心动图评估包括有效瓣口面积(AVA)(0.77 ± 0.21 cm2)、平均/峰值跨瓣压差(54.5 ± 12.2/88 ± 19.5mmHg)、左心室射血分数(LVEF)(21%=EF ≤ 40%)、收缩期肺动脉压(sPAP)(43.1 ± 11.6mmHg)。
所有患者均成功接受爱德华-SAPIEN 瓣膜(71.2%)或美敦力 CoreValve 瓣膜(28.8%)的 TAVI。
30 天、6 个月和 1 年的死亡率分别为 2.8%、11.2%和 17.5%。
在 16 个月的随访中,85.5%的患者存活,NYHA 心功能分级改善(2.8 ± 0.6 与 1.5 ± 0.7;p<0.001),sPAP 降低(43.1 ± 11.6mmHg 与 37.1 ± 7.7mmHg;p<0.001),EF ≤ 40%患者的 LVEF 增加(34.9 ± 6%与 43.5 ± 14.4%;p=0.006)。在 QOL 方面,49%的患者能独立行走,79%(≥85 岁的患者中为 39.5%)报告自我意识改善;58%(≥85 岁的患者中为 31.4%)报告 QOL“良好”,34%(≥85 岁的患者中为 16%)报告 QOL“符合年龄”,8%报告 QOL“差”。
TAVI 术可改善有症状严重主动脉瓣狭窄且年龄较大患者的临床结果和主观健康相关 QOL。